Copy

Click here if you cannot read this message

  Press Release 28 January 2019  
 
 
 

Bone Therapeutics holds successful event to highlight strength of cell and gene therapy in Wallonia

 

Gosselies, Belgium, January 28, 2019, 8pm CET - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, held an event at its headquarters this evening to highlight the growing contribution made by cell therapy to the Belgian biotechnology sector and to provide a broader update on the current sector environment.
 
Over the past decade, the biopharmaceutical industry in Belgian has significantly increased its contribution to the Belgian economy, employing a total of 28,294 people (1), ranking Belgium in the top 10 most innovative countries in the pharmaceutical sector and second in the top 10 European pharmaceutical exporters (2).
 
One sector of the biopharmaceutical industry stands out in particular: cell and gene therapy. Belgium now boasts several pioneers in cell and gene therapy, including Bone Therapeutics, Celyad, eTherRNA, Novadip, Promethera, TiGenix and other supporting companies such as Delphi Genetics, MaSTherCell and Ncardia,
 
With 80 clinical trials in cell or gene therapy products taking place between 2012 and 2018 and over 90 patent applications filed in the last ten years, Belgium has become a key hub for clinical development in cell and gene therapy.
 
In few years’ time, cell therapy has become a key focal point for Belgian biopharmaceutical industry. Belgium has a leading position in this field and is recognised worldwide for its excellence. I am very proud of Bone Therapeutics' contribution to this growth, which will result in the launch of two new advanced clinical trials in 2019,” said Thomas Lienard, Chief Executive Officer of Bone Therapeutics.
 
Financial support from the Walloon Region and SRIW
 
This thriving biotech ecosystem has benefited significantly from the support of the Walloon Region, an important source of funding for the sector. Over the past three years, the Walloon Region has provided Bone Therapeutics with non-dilutive financial support of around €7.60 million in the form of recoverable advances to finance important research and development programmes. The Walloon Region's total cumulative aid for research since the creation of Bone Therapeutics in 2006 amounts to €27.2 million.
 
The Société Régionale d'Investissement de Wallonie (SRIW), including Sofipole, one of its subsidiaries, has invested a cumulative amount of €8.8 million in Bone Therapeutics. Added to the other equity investments made by the SRIW group into other cell therapy companies (Promethera, Celyad, Ncardia and Novadip), the total amount invested amounts to €31.9 million.
 
The Walloon Minister of Economy and Research, Pierre-Yves Jeholet, who attended the event, added: “The Walloon Government is pleased to support the biopharmaceutical sector, a flagship sector synonymous with excellence in our region, which allows Wallonia to be an export leader in this field and actively contributes to our economic development. This is further evidenced by the grant of funding by the Region for the extension of the Biopark, which will celebrate its 20th anniversary in 2019, and which has succeeded in becoming a recognised ecosystem at a European level for biotechnology. Research and innovation are areas of great importance and we must continue to support innovative companies, such as Bone Therapeutics.
 
During the event, Bruno Colmant, Head of Macro Research at Bank Degroof Petercam, discussed the macroeconomic environment, the role played by public authorities in the development of high value-added companies and the impact of advanced technologies.
  
Professor Marc Jayankura (Erasmus Hospital - ULB) explained the difficulties encountered by patients, the current scientific limits and the advantages of cell therapy.
 
The Chairman of the Board of Directors of Bone Therapeutics, Jean Stéphenne, closed the presentations with a call for co-ordination and collaboration to maximise the key scientific strengths in the region: “To accelerate the development of cell therapy in Belgium, I consider it essential to strengthen collaborations between all the players in the sector and to pool resources with a common goal: to advance scientific research.
 
 
(1) Employment statistics Belgian National Social Security Office (Office national de Sécurité sociale, ONSS - Statistiques décentralisées), 30 June 2017
(2) Source: Pharma.be

 

 
 
 
 
 

Le communiqué de presse en français

Het persbericht in Nederlands

 
 

 
 

For further information, please contact:

Bone Therapeutics SA

Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Gunther De Backer, Head of Corporate Communications and Investor Relations
Tel: +32 (0) 71 12 10 00
investorrelations@bonetherapeutics.com

For Belgium Media Enquiries
Comfi

Sabine Leclercq
Tel: +32 (0)2 290 90 91
sabine.leclercq@comfi.be

For International Media Enquiries
Consilium Strategic Communications

Amber Fennell, Marieke Vermeersch, Jessica Hodgson, Angela Gray and Lindsey Neville
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries
NewCap Investor Relations & Financial Communications

Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau
Tel: + 33 (0)1 44 71 94 94
bone@newcap.eu

 

 
 

 
 
Follow us

Click here to unsubscribe
 
 

 
         Fond Européen

Le Fonds européen de développement régional et la Wallonie investissent dans votre avenir.

 
 
 
 

About Bone Therapeutics

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

The Company’s primary clinical focus is ALLOB, an allogeneic “off-the-shelf” cell therapy platform derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. In addition, the Company also has JTA-004, a viscosupplement in development for the treatment of knee osteoarthritis.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.

 

About SRIW

The SRIW (Société Régionale d'Investissement de Wallonie) contributes to the development of the economy by providing financial support for the development projects of Walloon or Walloon-based companies. It contributes to their growth, alongside private investors, through loans but also through equity investments.


Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

 
Bone Therapeutics S.A. • Rue Auguste Piccard, 37 • 6041 Gosselies • Belgium (Europe) • Phone: +32 (0) 71 12 10 00 • Fax: +32 (0) 71 12 10 01 • www.bonetherapeutics.com